Information Provided By:
Fly News Breaks for February 27, 2018
NITE
Feb 27, 2018 | 05:33 EDT
Mizuho analyst Difei Yang started Nightstar Therapeutics with a Buy rating and $20 price target. The analyst believes the company, with a Phase III pivotal trial of NSR-REP1 starting in the first half of 2018, is leading the way in gene therapy for the treatment of choroideremia, a rare inherited retinal disease. Yang sees "strong potential" for NSR-REP1 with additional upside from the company's earlier-stage pipeline products.
News For NITE From the Last 2 Days
There are no results for your query NITE